WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2]
WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Reports Third Quarter Fiscal Year 2013 Financial Results CHENGDU, China, May 14, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for third quarter of the fiscal year 2013. Third Quarter Fiscal Year 2013 Ended March 31,] [Tianyin Pharmaceutical Co., Inc. (TPI) F3Q13 Earnings Call May 15, 2013 9:00 AM EST Operator I would now like to turn the conference over to Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong - Chief Financial Officer Third quarter of fiscal year 2013 financial highlights – revenue $15.5 million compared with $14.4 million in the] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports Third Quarter Fiscal Year 2013 Financial
[TPI Reports Third Quarter Fiscal Year 2013 Financial Results CHENGDU, China, May 14, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for third quarter of the fiscal year 2013. Third Quarter Fiscal Year 2013 Ended March 31,] [Tianyin Pharmaceutical Co., Inc. (TPI) F3Q13 Earnings Call May 15, 2013 9:00 AM EST Operator I would now like to turn the conference over to Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong - Chief Financial Officer Third quarter of fiscal year 2013 financial highlights – revenue $15.5 million compared with $14.4 million in the] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)
[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2013 Weibing Lu Chief Executive Officer EX-32.1 4 v344542_ex32-1.htm EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2013 Bing Mei Chief Financial Officer EX-32.2 5 v344542_ex32-2.htm EX-32.2]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q:
[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2013 Weibing Lu Chief Executive Officer EX-32.1 4 v344542_ex32-1.htm EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. May 15, 2013 Bing Mei Chief Financial Officer EX-32.2 5 v344542_ex32-2.htm EX-32.2]
BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: May 15, 2013 Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: May 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 5 ex32-2.htm]
BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2013
[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: May 15, 2013 Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: May 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 5 ex32-2.htm]
TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number, x o x] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong James Jiayuan Tong Chief Financial Officer, Director]
TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly
[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number, x o x] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong James Jiayuan Tong Chief Financial Officer, Director]
